Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ImmunoScape logo — Transforming Cancer Therapy with Our Novel Seed-and-Boost Ap...

ImmunoScape

Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach

Founded 2016 Singapore Singapore 24 employees Total: $41.25M Biotechnology, Life Sciences

General Information

Company Name ImmunoScape
Founded Year 2016
Location Singapore Singapore
Founders / Decision Makers
Team member
Employees 24
Industries Biotechnology, Life Sciences
Business Model B2B, B2B2C
Revenue Model Licensing, Performance Based
Offices as of Oct 2026
Singapore, Singapore Cambridge, United States
Social

BounceWatch is an independent company data service, not affiliated with ImmunoScape. To contact ImmunoScape, visit immunoscape.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImmunoScape compare?

A PDF of ImmunoScape and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImmunoScape soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ImmunoScape

ImmunoScape, founded in 2016 and headquartered in Singapore, is at the forefront of innovating cancer therapy within the Biotechnology and Life Sciences industries. Their slogan, "Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach," encapsulates their mission.

The company pioneers a mix of proprietary TCR T cells with validated Immuno-STAT T cell engagers, remedying current therapy limitations by enhancing in vivo expansion of tumor-targeting T-cells. This integration promises safer, more effective cancer therapies and improved patient experiences. ImmunoScape is actively progressing with IND-enabling studies, with a focus on swift clinical trial initiation.

Their ability to transform cell therapy has attracted notable investment interest, highlighted by an early VC round backed by EDBI as of 01 June 2025. ImmunoScape stands out for investors seeking impactful advancements in cancer treatment.

Business keywords: Cancer Therapy, Seed-and-Boost Approach, TCR T Cells, Immuno-STAT T Cell Engagers, Cell Therapy, In Vivo Expansion, IND-Enabling Studies, Immune Profiling, Deep Immunomics Platform, Mass Cytometry, Single Cell Sequencing, Bioinformatics, Oncology, Immunotherapy, Immunomics

Services & Products

Development of novel cancer therapies
Personalized treatment approaches
Research and development in oncology

Target Customers

Healthcare professionals Oncologists Biotechnology researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 1
EDBI
EDBI
01 Jun 2025
Grant $250.00K 1
ScaleReady
01 Sep 2024
Early VC $14.00M 3
Amgen Ventures Anzu Partners EDBI
Amgen Ventures, Anzu Partners +1
01 Sep 2022
Early VC $14.00M 3
Anzu Partners EDBI The University of Tokyo Edge Capital
Anzu Partners, EDBI +1
01 Apr 2021
Early VC $11.00M 2
Anzu Partners The University of Tokyo Edge Capital
Anzu Partners, The University of Tokyo Edge Capital
01 Aug 2020
Series A SGD2.00M 1
Tembusu Partners
Tembusu Partners
01 Nov 2016

Latest News

View All
ImmunoScape Appoints Peter Olagunju as Chief Executive Officer — The National Law Review
ImmunoScape Appoints Peter Olagunju as Chief Executive Officer
The National Law Review Oct 12, 2026

ImmunoScape Alternatives & Competitors

View All Alternatives
ImmunoScape vs
Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC.
Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC. China

杭州艾沐蒽生物科技有限公司

Series A
1 employees
Biotechnology, Health Care
ImmunoScape vs
Kiromic Biopharma, Inc.
Kiromic Biopharma, Inc. United States

Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing technologies to...

Post-IPO Equity
17 employees
Biopharma, Biotechnology
ImmunoScape vs
LAVA Therapeutics N.V.
LAVA Therapeutics N.V. The Netherlands

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer

Series C
7 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About ImmunoScape

Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach
ImmunoScape was founded in 2016.
ImmunoScape is headquartered in Singapore. As of Oct 2026, it also has offices in Singapore, Singapore and Cambridge, United States.
ImmunoScape operates in Biotechnology and Life Sciences. Its work centres on Cancer Therapy, Seed-and-Boost Approach, TCR T Cells and Immuno-STAT T Cell Engagers. Its customers include Healthcare professionals, Oncologists and Biotechnology researchers.
ImmunoScape has a B2B and B2B2C business model. Its revenue comes from Licensing and Performance Based.
ImmunoScape has approximately 24 employees.
ImmunoScape has completed 6 funding rounds, raising a total of $41.25M.
ImmunoScape offers: Development of novel cancer therapies, Personalized treatment approaches, Research and development in oncology.
Top alternatives and competitors to ImmunoScape include Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC., Kiromic Biopharma, Inc., LAVA Therapeutics N.V.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunoScape and Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImmunoScape, https://bouncewatch.com/company/immunoscape, updated 8 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes